Trial re-evaluates routine defibrillator implantation after myocardial infarction.

The PROFID EHRA trial will be the first randomised adequately powered assessment of the potential benefit of ICD therapy in myocardial infarction survivors with reduced LVEF under contemporary optimal medical therapy. Keywords: Cardiac Death; Cardiology; Cardiovascular Diseases and Conditions; Defibrillators; Drugs and Therapies; European Society of Cardiology; Genetics; Health and Medicine; Heart Arrest; Heart Attack; Heart Disease; Heart Disorders and Diseases; Heart Failure; Hospitals; Medical Devices; Myocardial Infarction; Myocardial Ischemia; Pharmaceuticals; Risk and Prevention; Sudden Cardiac Death; Sudden Death; Therapy; Vascular Diseases and Conditions EN Cardiac Death Cardiology Cardiovascular Diseases and Conditions Defibrillators Drugs and Therapies European Society of Cardiology Genetics Health and Medicine Heart Arrest Heart Attack Heart Disease Heart Disorders and Diseases Heart Failure Hospitals Medical Devices Myocardial Infarction Myocardial Ischemia Pharmaceuticals Risk and Prevention Sudden Cardiac Death Sudden Death Therapy Vascular Diseases and Conditions 1357 1357 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Amsterdam, Netherlands - 26 Aug 2023: Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial infarction survivors with heart failure still an adequate therapy for prevention of sudden cardiac death?. [Extracted from the article]